Eur Rev Med Pharmacol Sci 2019; 23 (18): 8018-8027

DOI: 10.26355/eurrev_201909_19018

Effectiveness of the new generation transcatheter aortic valve in the real life studies. Review and meta-analysis

M.C. Acconcia, Q. Caretta, L. Monzo, G. Tanzilli, A. Sili Scavalli, D. Sergi, M. Di Luozzo, M. Marchei, M. Chiocchi, F. Romeo, C. Gaudio

Department of Cardiovascular Disease, “Sapienza” University of Rome, Rome, Italy. qcaretta@unifi.it


OBJECTIVE: The aim of the meta-analysis was to assess post-procedural outcome of the new generation of transcatheter aortic valve implantation (TAVI) devices, focusing on the transfemoral and balloon-expandable SAPIEN 3 (Edwards Lifesciences Inc., Irvine, CA, USA), the self-expanding CoreValveTM Evolut series R and PRO (R/PRO)TM (Medtronic Inc., Minneapolis, MN, USA) and ACURATE neoTM transcatheter aortic valve (Symetis SA, a Boston Scientific company, Ecublens, Switzerland).
MATERIALS AND METHODS: All observational studies were retrieved through PubMed computerized database from January 2014 until June 30th, 2019. The risk difference (RD) with the 95% confidence interval (CI) was used to assess the effectiveness of the intervention under comparison. The primary end point was 30-day mortality. Safety end points included: (i) stroke, (ii) moderate/severe paravalvular leak, and (iii) the need for new permanent pacemaker implantation.
RESULTS: Meta-analysis demonstrated no significant differences as regards to either 30-day mortality or stroke for all the groups of prostheses under comparison. ACURATE neo was associated with significantly less new permanent pacemaker implantation compared to SAPIEN 3 (RD: -0.06; 95% CI -0.08 to -0.03; p<0.0001; I2=0%) or to EVOLUT R/PRO (RD: -0.06; 95% CI -0.09 to -0.02; p=0.0009; I2=0%). A significant reduction of new permanent pacemaker need was observed in the group of patients implanted with SAPIEN 3 compared to EVOLUT R/PRO (RD: -0.07; 95% CI -0.09 to -0.04; p<0.00001; I2=7%). The occurrence of moderate/severe leak was significantly increased in the group of patients implanted with ACURATE neo vs. SAPIEN 3 (RD: 0.04; 95% CI 0.02 to 0.05; p<0.00001; I2=0%). No significant differences were found between ACURATE neo vs. EVOLUT R/PRO (RD: -0.01; 95% CI -0.04 to 0.02; p=0.69; I2=0%) and between SAPIEN 3 vs. EVOLUT R/PRO (RD: -0.01; 95% CI -0.04 to 0.01; p=0.28; I2=73%).
CONCLUSIONS: The results of the meta-analysis show that: (1) ACURATE neo was associated with significantly less new permanent pacemaker implantation than SAPIEN 3 and EVOLUT R/PRO; (2) SAPIEN 3 had significantly lower occurrence of moderate/severe valvular leak than ACURATE neo.

Free PDF Download

To cite this article

M.C. Acconcia, Q. Caretta, L. Monzo, G. Tanzilli, A. Sili Scavalli, D. Sergi, M. Di Luozzo, M. Marchei, M. Chiocchi, F. Romeo, C. Gaudio
Effectiveness of the new generation transcatheter aortic valve in the real life studies. Review and meta-analysis

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 18
Pages: 8018-8027
DOI: 10.26355/eurrev_201909_19018